What is NightWare?
NightWare is a pioneering prescription digital therapeutic system designed to alleviate sleep disturbances, specifically targeting Nightmare Disorder and PTSD-related nightmares in adults. As the first FDA-cleared digital therapeutic of its kind, NightWare offers a low-risk treatment that demonstrably improves sleep quality within two weeks, crucially without waking the patient. The system's adaptive nature allows it to personalize therapy based on individual sleep patterns, and it can be integrated with existing PTSD treatment protocols. NightWare's mission is to equip healthcare professionals and their patients with advanced, effective solutions for enhanced sleep and overall well-being.
How much funding has NightWare raised?
NightWare has raised a total of $1.4M across 2 funding rounds:
Private Equity
$1.1M
Private Equity
$250K
Private Equity (2025): $1.1M, investors not publicly disclosed
Private Equity (2026): $250K, investors not publicly disclosed
What's next for NightWare?
The substantial enterprise-level capital infusion positions NightWare for accelerated growth and market expansion. This strategic investment is expected to fuel further research and development, enhance the company's commercialization efforts, and potentially broaden its therapeutic applications. With its unique FDA clearance and proven efficacy, NightWare is poised to become a leader in digital sleep health, addressing a critical unmet need in mental health and wellness. The company's trajectory suggests a focus on scaling operations and solidifying its position as a key player in the digital therapeutics landscape.
See full NightWare company page
